by nobilistx | Jul 22, 2020 | Uncategorized |
Nobilis Therapeutics, a biopharmaceutical company today announced that the U.S. Food & Drug Administration (FDA) has allowed it to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with Panic Disorder. PORTLAND, ORE. (PRWEB) JULY...